Russell Schundler Sells 1,063 Shares of Liquidia Co. (NASDAQ:LQDA) Stock

Liquidia Co. (NASDAQ:LQDA) General Counsel Russell Schundler sold 1,063 shares of the business’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $11.51, for a total value of $12,235.13. Following the sale, the general counsel now owns 487,328 shares in the company, valued at approximately $5,609,145.28. This trade represents a 0.22 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Russell Schundler also recently made the following trade(s):

• On Monday, October 14th, Russell Schundler sold 2,576 shares of Liquidia stock. The stock was sold at an average price of $11.11, for a total value of $28,619.36.

Liquidia Stock Performance

NASDAQ LQDA traded up $0.03 on Tuesday, hitting $11.26. The stock had a trading volume of 1,423,986 shares, compared to its average volume of 972,832. Liquidia Co. has a 52-week low of $6.83 and a 52-week high of $16.99. The firm has a 50-day moving average of $10.76 and a 200-day moving average of $11.34.

Wall Street Analyst Weigh In

LQDA has been the subject of several recent analyst reports. Bank of America reduced their price objective on shares of Liquidia from $24.00 to $23.00 and set a “buy” rating for the company in a research report on Tuesday, August 20th. Needham & Company LLC reaffirmed a “buy” rating and issued a $19.00 price target on shares of Liquidia in a research note on Thursday, November 14th. HC Wainwright restated a “buy” rating and issued a $29.00 target price on shares of Liquidia in a research note on Thursday, November 14th. Scotiabank began coverage on Liquidia in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $30.00 price target on the stock. Finally, BTIG Research reduced their price objective on Liquidia from $29.00 to $25.00 and set a “buy” rating for the company in a research note on Monday, August 19th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, Liquidia has an average rating of “Moderate Buy” and a consensus price target of $24.00.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Whitefort Capital Management LP raised its stake in Liquidia by 119.8% in the third quarter. Whitefort Capital Management LP now owns 1,702,025 shares of the company’s stock worth $17,020,000 after buying an additional 927,546 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Liquidia by 144.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 390,257 shares of the company’s stock valued at $3,903,000 after purchasing an additional 230,820 shares during the period. Anson Funds Management LP purchased a new stake in Liquidia in the third quarter worth $1,764,000. Sapient Capital LLC bought a new stake in Liquidia during the third quarter worth about $1,336,000. Finally, BNP Paribas Financial Markets raised its stake in Liquidia by 735.1% during the third quarter. BNP Paribas Financial Markets now owns 140,190 shares of the company’s stock valued at $1,402,000 after buying an additional 123,402 shares during the last quarter. 64.54% of the stock is currently owned by institutional investors.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).